Dyne Therapeutics (DYN)
Develops targeted genetic medicines for neuromuscular diseases through its FORCE delivery platform.
$16.50
vs last close−0.64 (−3.74%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 102.72% | 191.82M shares | |
|---|---|---|---|
| 254 holders · as of Jun 30, 2026 | |||
| Insiders | 2.53% | 4.72M shares | |
| 8 holders · as of Sep 8, 2026 | |||
| Strategic holders | 7.31% | 13.65M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 112.56% | ||
186.75M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 112.56%; nothing is left for Other.
13F, as of Jun 30, 2026
254 holders · 191.82M shares · 50 new positions · 141 increased · 76 reduced · 32 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30.91M | 16.55% | +126.5K | Aug 14, 2026 |
| BlackRock, Inc. | 12.40M | 6.64% | +704.5K | Aug 7, 2026 |
| Jupiter Topco LLC | 12.00M | 6.42% | +12.00Mnew | Aug 14, 2026 |
| FMR LLC | 11.21M | 6.00% | +2.30M | Aug 13, 2026 |
| State Street Corp | 7.46M | 3.99% | +804.5K | Aug 7, 2026 |
| Orbis Allan Gray Ltd | 7.01M | 3.75% | +244.3K | Aug 14, 2026 |
| Atlas Venture Life Science Advisors, LLC | 6.80M | 3.64% | −2.33M | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.31M | 3.38% | −94.1K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.70% | 30.79M | 13G | May 15, 2026 |
| Janus Henderson Group PLC | 8.30% | 13.65M | 13G | May 15, 2026 |
| Ein #incl. Janus Henderson Group plc | 6.80% | 6.81M | Nov 14, 2024 | |
| BlackRock, Inc. | 5.80% | 6.58M | 13G | Apr 17, 2025 |
| FMR LLC | 5.40% | 8.91M | 13G | May 6, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 8, 2026 | John Coxdirector, officer: CEO & President | Sale | 5,658 | $18.88 | 357,507 |
| Sep 8, 2026 | Douglas Kerrofficer: Chief Medical Officer | Sale | 1,290 | $18.88 | 162,564 |
| Sep 4, 2026 | Douglas Kerrofficer: Chief Medical Officer | Sale | 3,745 | $24.35 | 163,854 |
| Sep 8, 2026 | Johanna Friedl-Nadererofficer: Chief Commercial Officer | Sale | 185 | $18.88 | 152,897 |
| Sep 4, 2026 | Johanna Friedl-Nadererofficer: Chief Commercial Officer | Sale | 900 | $24.35 | 153,082 |
| Aug 13, 2026 | Jason P. Rhodesdirector | Sale · 3 lots | 426,412 | $26.20 | 751,411 |
| Aug 14, 2026 | Jason P. Rhodesdirector | Sale · 3 lots | 2,160,516 | $25.00 | 428,946 |
| Aug 13, 2026 | Johanna Friedl-Nadererofficer: Chief Commercial Officer | Sale | 226 | $26.28 | 153,982 |
| Aug 13, 2026 | Erick Luceraofficer: Chief Financial Officer | Sale | 1,797 | $26.28 | 119,766 |
| Aug 13, 2026 | John Coxdirector, officer: CEO & President | Sale | 4,986 | $26.28 | 363,165 |
House and Senate disclosures
Not reported.